Literature DB >> 26359227

Effects of cholinesterase inhibitor on brain activation in Alzheimer's patients measured with functional near-infrared spectroscopy.

Florian G Metzger1,2, Ann-Christine Ehlis3, Florian B Haeussinger3,4, Andreas J Fallgatter3,5, Katja Hagen3.   

Abstract

RATIONALE: Neurobiological effects of neuropsychiatric medication can contribute to the understanding of mechanisms of action and to the evaluation of target medication effects. Cholinesterase inhibitors (ChEI) have been used in patients with Alzheimer's disease (AD) for years with only small knowledge about the underlying neurobiological effects. The measurement of brain activation links neurobiological and functional aspects but is challenging in the group of demented patients; here, an alternative method, functional near-infrared spectroscopy (fNIRS), is introduced to measure those medication effects.
OBJECTIVES: The current study investigated the influence of ChEI on cortical activation of patients with AD measured using fNIRS during a verbal fluency task (VFT).
METHODS: In this study, 24 probable AD patients were investigated three times using fNIRS: before medication with rivastigmine was given (t0), when the medication was at the target dose after 4 weeks (t1), and after the target dose was kept constant for a further 8 weeks (t2).
RESULTS: The results show a concentration increase of oxygenated hemoglobin as measured with fNIRS from t0 to t2 in speech relevant areas and a general decrease in prefrontal areas. Behaviorally, an improvement was found for the VFT used to measure cortical activation during fNIRS. In the neuropsychological test battery, no significant changes were found, yet high effect sizes for the mini mental status examination, immediate and delayed word list recall were found.
CONCLUSIONS: The results indicate a positive effect of ChEI on cognitive function. The underlying cortical changes can be imaged using fNIRS.

Entities:  

Keywords:  Alzheimer’s dementia; Cholinesterase inhibitors; Functional near-infrared spectroscopy; Medication against dementia; Rivastigmine patch

Mesh:

Substances:

Year:  2015        PMID: 26359227     DOI: 10.1007/s00213-015-4066-z

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  45 in total

1.  Established donepezil treatment modulates task relevant regional brain activation in early Alzheimer's disease.

Authors:  W J McGeown; M F Shanks; K E Forbes-McKay; G D Waiter; I Elrick; M G Venneri; A Venneri
Journal:  Curr Alzheimer Res       Date:  2010-08       Impact factor: 3.498

2.  Donepezil therapy in clinical practice: a randomized crossover study.

Authors:  S M Greenberg; M K Tennis; L B Brown; T Gomez-Isla; D L Hayden; D A Schoenfeld; K L Walsh; C Corwin; K R Daffner; P Friedman; M E Meadows; R A Sperling; J H Growdon
Journal:  Arch Neurol       Date:  2000-01

3.  Inhibition of hippocampal function in mild cognitive impairment: targeting the cholinergic hypothesis.

Authors:  G Grön; I Brandenburg; A P Wunderlich; M W Riepe
Journal:  Neurobiol Aging       Date:  2006-01       Impact factor: 4.673

4.  Improved verbal learning after outpatient oral physostigmine therapy in patients with dementia of the Alzheimer type.

Authors:  S Sevush; A Guterman; A V Villalon
Journal:  J Clin Psychiatry       Date:  1991-07       Impact factor: 4.384

Review 5.  Revisiting the cholinergic hypothesis of behavioral and psychological symptoms in dementia of the Alzheimer's type.

Authors:  Tanya Pinto; Krista L Lanctôt; Nathan Herrmann
Journal:  Ageing Res Rev       Date:  2011-02-01       Impact factor: 10.895

6.  Responders to ChEI treatment of Alzheimer's disease show restitution of normal regional cortical activation.

Authors:  Annalena Venneri; William J McGeown; Michael F Shanks
Journal:  Curr Alzheimer Res       Date:  2009-04       Impact factor: 3.498

Review 7.  Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline.

Authors:  Parminder Raina; Pasqualina Santaguida; Afisi Ismaila; Christopher Patterson; David Cowan; Mitchell Levine; Lynda Booker; Mark Oremus
Journal:  Ann Intern Med       Date:  2008-03-04       Impact factor: 25.391

Review 8.  Neuropsychiatric symptoms in the dementias.

Authors:  Frédéric Assal; Jeffrey L Cummings
Journal:  Curr Opin Neurol       Date:  2002-08       Impact factor: 5.710

9.  Effects of cholinergic enhancement on visual stimulation, spatial attention, and spatial working memory.

Authors:  P Bentley; M Husain; R J Dolan
Journal:  Neuron       Date:  2004-03-25       Impact factor: 17.173

10.  Prolonged cholinergic enrichment influences regional cortical activation in early Alzheimer's disease.

Authors:  William J McGeown; Michael F Shanks; Annalena Venneri
Journal:  Neuropsychiatr Dis Treat       Date:  2008-04       Impact factor: 2.570

View more
  3 in total

1.  Study of memory deficit in Alzheimer's disease by means of complexity analysis of fNIRS signal.

Authors:  David Perpetuini; Roberta Bucco; Michele Zito; Arcangelo Merla
Journal:  Neurophotonics       Date:  2017-09-26       Impact factor: 3.593

2.  Brain activation in frontotemporal and Alzheimer's dementia: a functional near-infrared spectroscopy study.

Authors:  Florian G Metzger; Betti Schopp; Florian B Haeussinger; Katja Dehnen; Matthis Synofzik; Andreas J Fallgatter; Ann-Christine Ehlis
Journal:  Alzheimers Res Ther       Date:  2016-12-08       Impact factor: 6.982

3.  Functional Near-Infrared Spectroscopy in the Study of Speech and Language Impairment Across the Life Span: A Systematic Review.

Authors:  Lindsay K Butler; Swathi Kiran; Helen Tager-Flusberg
Journal:  Am J Speech Lang Pathol       Date:  2020-07-08       Impact factor: 2.408

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.